Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

ProMIS Neurosciences Inc. is a development stage biotechnology company. The Company is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), an alpha-synucleinopathy. Its proprietary target discovery engine applies a thermodynamic, computational discovery platform - ProMIS and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product portfolio includes PMN310 / Amyloid-beta, PMN267 / TDP-43, and PMN442 / Alpha-synuclein. The Company plans to investigate additional synucleinopathies, including Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Its wholly owned subsidiary is ProMIS Neurosciences (US) Inc.


NDAQ:PMN - Post by User

Bullboard Posts
Post by farmerjaneon Apr 22, 2013 11:00am
128 Views
Post# 21289444

QPS- Validation

QPS- Validation

Discussing QPS last week in looking at there Web site and scrolling news articles, three of the nine have to do with Amorfix and the third one is of particular interest to me. 

1) Amorfix and QPS collaboration- nothing new here.

2) Neuropharmacology- In Vitro models of Alzhemizers disease, explantion of there animal models.

3) Early stage clinical-  If you recall the article from Alzforum on July 23,2012, it was pointed out there is some scientific questions about the storage and handling of CSF samples. From this article " One problem might be the storage of CSF samples. The best approach, Felsenstein suggested, is to assay fresh CSF and limit manipulation to simple dilution of the sample."

QPS news release "Blood and CSF samples were collected over 30 hours ", Furthermore ,all CSF samples tested reflected non-negligible levels of Acetylcholine, an Alzheimer's Disease-sensitive biomarker, indicating that the CSF collected was of good quality " 

Bullboard Posts